Cogent Biosciences (COGT) Price & Analysis

Compare

646 Followers

COGT Stock Chart & Stats

$14.72

-$0.07(-0.91%)

At close: Jan 08 4:00 PM EST

$14.72

-$0.07(-0.91%)

Day’s Range― - ―

52-Week Range$3.72 - $17.15

Previous CloseN/A

Volume181.15K

Average Volume (3M)2.40M

Market Cap

$1.97B

Enterprise ValueN/A

Total Cash (Recent Filing)$237.85M

Total Debt (Recent Filing)$60.66M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Mar 17, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding139,700,790

10 Day Avg. Volume2,832,473

30 Day Avg. Volume2,395,331

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$26.43

Price Target Upside79.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trials And FDA DesignationBezuclastinib recently received FDA Breakthrough Therapy Designation for non-advanced systemic mastocytosis patients previously treated with avapritinib and patients with Smoldering Systemic Mastocytosis.

Financial Health And Market PotentialCogent has $430M in pro-forma cash, cash equivalents, and marketable securities, expected to fund operations into 2027, including early commercial launch activities of bezuclastinib.

Market Share And Commercial PotentialBezuclastinib has the potential to address a collective $3 billion U.S. total addressable market across all three indications.

Bears Say

Competitive Pressures And Market ChallengesKOLs mostly plan to reserve use of bezuclastinib for patients who have insufficient response to AYVAKIT.

Financial Concerns And Cash BurnAnnualized cash burn is $239.0 million, with approximately 2.5 years of cash left, which could be a concern if the company does not secure additional funding or reach profitability.

Short Interest And Investor SentimentShort Interest is relatively high at 15.1% of the float, which may indicate that a significant number of investors are betting against the stock.

Cogent Biosciences News

Cogent Biosciences files automatic mixed securities shelf

16:44 EST Cogent Biosciences (COGT) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

10h ago

COGT

Cogent Biosciences reports Q3 net loss $80.9M vs. $70.6M last year

“Cogent had a very productive and busy third quarter and we now find ourselves weeks away from reporting...

5d ago

COGT

Cogent Biosciences sees cash runway into 2027

As of September 30, 2025, cash, cash equivalents and marketable securities were $390.9 million, as compared to $345.5...

5d ago

COGT

JPMorgan ups Cogent Biosciences target, adds ‘Positive Catalyst Watch’

JPMorgan analyst Anupam Rama raised the firm’s price target on Cogent Biosciences (COGT) to $44 from $30 and...

18d ago

COGT

Cogent Biosciences announces FDA BTD for bezuclastinib

Cogent Biosciences (COGT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD,...

19d ago

COGT

Cogent Biosciences initiated with a Hold at Stifel

Stifel initiated coverage of Cogent Biosciences (COGT) with a Hold rating and $16 price target The firm says...

23d ago

COGT

Cogent Biosciences Advances Precision Therapies in Q3 2025

Cogent Biosciences, Inc. ( ($COGT) ) has released its Q3 earnings. Here is a breakdown of the information...

3d ago

COGT

Cogent Biosciences: Hold Rating Amid Anticipated Positive Data and Pipeline Developments

Needham analyst Ami Fadia has maintained their neutral stance on COGT stock, giving a Hold rating on October...

4d ago

COGT

Cogent Biosciences Advances FGFR2/3 Inhibitor Study in Cancer Treatment

Cogent Biosciences, Inc. (($COGT)) announced an update on their ongoing clinical study. Study Overview: Cogent Biosciences, Inc. is...

12d ago

COGT

Cogent Biosciences’ Phase 2 Study on Bezuclastinib: A Potential Game-Changer for Advanced Systemic Mastocytosis

Cogent Biosciences, Inc. (($COGT)) announced an update on their ongoing clinical study. Cogent Biosciences, Inc. is conducting a...

12d ago

COGT

Promising Outlook for Cogent Biosciences: Buy Rating Backed by FDA Breakthrough Designation and Strong Phase 3 Trial Prospects

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Cogent Biosciences. The associated price target...

19d ago

COGT

Cogent Biosciences added to Analyst Current Favorites list at Raymond James

Raymond James added Cogent Biosciences (COGT) to the firm’s Analyst Current Favorites list. The list contains the current...

2M ago

COGT

Cogent Biosciences Signs Lease for New Headquarters

An update from Cogent Biosciences ( ($COGT) ) is now available. On September 5, 2025, Cogent Biosciences entered...

2M ago

COGT

Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib’s Potential and Expected 68.2% Share Price Return

Analyst David Lebowitz from Citi maintained a Buy rating on Cogent Biosciences and keeping the price target at...

2M ago

COGT

COGT FAQ

What was Cogent Biosciences’s price range in the past 12 months?

Cogent Biosciences lowest stock price was $3.72 and its highest was $17.15 in the past 12 months.

What is Cogent Biosciences’s market cap?

Cogent Biosciences’s market cap is $1.97B.

When is Cogent Biosciences’s upcoming earnings report date?

Cogent Biosciences’s upcoming earnings report date is Mar 17, 2026 which is in 129 days.

How were Cogent Biosciences’s earnings last quarter?

Cogent Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.525 by -$0.055.

Is Cogent Biosciences overvalued?

According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cogent Biosciences pay dividends?

Cogent Biosciences does not currently pay dividends.

What is Cogent Biosciences’s EPS estimate?

Cogent Biosciences’s EPS estimate is -0.52.

How many shares outstanding does Cogent Biosciences have?

Cogent Biosciences has 139,700,790 shares outstanding.

What happened to Cogent Biosciences’s price movement after its last earnings report?

Cogent Biosciences reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.525. Following the earnings report the stock price went down -4.908%.

Which hedge fund is a major shareholder of Cogent Biosciences?

Currently, no hedge funds are holding shares in COGT

Cogent Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-95.40%

Trailing 12-Months

Asset Growth

10.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies to treat genetically driven diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its core product pipeline, which includes experimental therapies for specific genetic mutations linked to rare disorders and cancers. Cogent Biosciences aims to address unmet medical needs through targeted treatment options, leveraging its expertise in genetic and molecular biology.

Cogent Biosciences (COGT) Earnings & Revenues

Historic Earnings Reports

COGT Stock 12 Month Forecast

Average Price Target

$26.43

▲(79.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","45":"$45","14.25":"$14.25","24.5":"$24.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,14.25,24.5,34.75,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.3,18.430769230769233,20.56153846153846,22.692307692307693,24.823076923076925,26.953846153846154,29.084615384615386,31.215384615384615,33.34615384615385,35.47692307692308,37.607692307692304,39.738461538461536,41.86923076923077,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.3,17.07923076923077,17.85846153846154,18.63769230769231,19.416923076923077,20.196153846153848,20.975384615384616,21.754615384615384,22.533846153846156,23.313076923076924,24.092307692307692,24.871538461538464,25.65076923076923,{"y":26.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.3,16.276923076923076,16.253846153846155,16.23076923076923,16.20769230769231,16.184615384615384,16.161538461538463,16.138461538461538,16.115384615384617,16.092307692307692,16.06923076923077,16.046153846153846,16.023076923076925,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >